Breast cancer hijacks immune alarm: turning defense into cancer-fueling inflammation
Peer-Reviewed Publication
Updates every hour. Last Updated: 12-Jun-2026 18:15 ET (12-Jun-2026 22:15 GMT/UTC)
Researchers uncover a cunning new trick by which breast cancer cells evade immune attack. While the cGAS-STING pathway normally detects cytosolic DNA and activates anti-tumor immunity via IRF3-interferon signaling, aggressive tumors overexpress a long noncoding RNA, FAM83H-AS1, redirecting cGAS-STING signaling toward NF-κB-driven chronic inflammation that supports tumor growth. Critically, this shift creates a therapeutic vulnerability: NF-κB upregulates PD-L1, rendering these tumors highly susceptible to existing immunotherapies. This discovery reveals both a key mechanism for how cancer evades immunity and a promising way to fight back.
Scientists have created a groundbreaking, fully implantable neurostimulator made entirely of soft hydrogel to treat inflammatory bowel disease (IBD). Unlike traditional rigid and wired implants, this wireless device gently wraps around the splenic nerve. It receives power through the skin to deliver electrical pulses that calm gut inflammation by rebalancing the immune system. In animal studies, the device significantly alleviated colitis symptoms without causing scar tissue formation, paving the way for a new class of soft, bioelectronic therapies for chronic diseases.
A recent study comprehensively evaluated the secondary metabolite diversity and in vitro antidiabetic activity of Sanghuangporus quercicola under various culture conditions, highlighting the medicinal fungus’s immense potential for developing new antidiabetic drugs and functional foods.
A new study published in Engineering reveals the global spread of tmexCD1-toprJ1-positive Klebsiella pneumoniae, highlighting its multidrug resistance and transmission across ecological niches. The research underscores the urgent need for antimicrobial stewardship and continuous monitoring to combat this emerging public health threat.
A new study finds that since 2013, expansive growth has been seen in affiliations between fertility clinics and private equity firms, and that over half of IVF cycles in the country in 2023 were done at clinics affiliated with private equity firms.